AR090207A1 - Anticuerpos recombinantes con especificidad dual por gangliosidos y su uso - Google Patents
Anticuerpos recombinantes con especificidad dual por gangliosidos y su usoInfo
- Publication number
- AR090207A1 AR090207A1 ARP130100653A ARP130100653A AR090207A1 AR 090207 A1 AR090207 A1 AR 090207A1 AR P130100653 A ARP130100653 A AR P130100653A AR P130100653 A ARP130100653 A AR P130100653A AR 090207 A1 AR090207 A1 AR 090207A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibodies
- dual specificity
- gangliosids
- recombinant antibodies
- antigens
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
La presente se relaciona con anticuerpos monoclonales y fragmentos de estos anticuerpos, con especificidad dual y alta afinidad por los gangliósidos N-acetil GM3 y N-glicolil GM3, y que no reconocen otros gangliósidos. En otro aspecto, la presente se relaciona con el uso de estos anticuerpos y sus fragmentos en la terapia de tumores que tienen una expresión significativa de cualquiera de los dos antígenos reconocidos por estos anticuerpos, o una expresión mixta de ambos antígenos. Así como al uso de estos anticuerpos en el diagnóstico de tumores que expresen al menos uno de los antígenos. Composición farmacéutica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20120035A CU24120B1 (es) | 2012-03-01 | 2012-03-01 | Anticuerpos recombinantes con especificidad dual por los gangliósidos n-acetil gm3 y n-glicolil gm3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR090207A1 true AR090207A1 (es) | 2014-10-29 |
Family
ID=48039960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130100653A AR090207A1 (es) | 2012-03-01 | 2013-02-28 | Anticuerpos recombinantes con especificidad dual por gangliosidos y su uso |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9527920B2 (es) |
| EP (1) | EP2821417A2 (es) |
| JP (1) | JP5933044B2 (es) |
| KR (1) | KR20140126349A (es) |
| CN (1) | CN104136463B (es) |
| AR (1) | AR090207A1 (es) |
| AU (1) | AU2013225453A1 (es) |
| CA (1) | CA2865050A1 (es) |
| CL (1) | CL2014002236A1 (es) |
| CO (1) | CO7051011A2 (es) |
| CU (1) | CU24120B1 (es) |
| EA (1) | EA201491618A1 (es) |
| HK (1) | HK1198654A1 (es) |
| IL (1) | IL234394A0 (es) |
| MX (1) | MX2014010456A (es) |
| PE (1) | PE20142277A1 (es) |
| PH (1) | PH12014501950A1 (es) |
| SG (1) | SG11201405151YA (es) |
| TN (1) | TN2014000330A1 (es) |
| TW (1) | TW201348259A (es) |
| WO (1) | WO2013127373A2 (es) |
| ZA (1) | ZA201407043B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU24120B1 (es) * | 2012-03-01 | 2015-08-27 | Ct De Inmunología Molecular | Anticuerpos recombinantes con especificidad dual por los gangliósidos n-acetil gm3 y n-glicolil gm3 |
| CN104651314B (zh) * | 2015-02-14 | 2018-06-19 | 百泰生物药业有限公司 | 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子 |
| EP3277713A1 (en) * | 2015-03-31 | 2018-02-07 | VHsquared Limited | Polypeptides |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4107154A1 (de) | 1990-10-11 | 1992-04-16 | Boehringer Mannheim Gmbh | Monoklonale antikoerper gegen melanom |
| CU22731A1 (es) | 1998-02-05 | 2002-02-28 | Centro Inmunologia Molecular | Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen |
| CU23403A1 (es) * | 2003-04-23 | 2009-08-04 | Centro Inmunologia Molecular | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
| CU24120B1 (es) * | 2012-03-01 | 2015-08-27 | Ct De Inmunología Molecular | Anticuerpos recombinantes con especificidad dual por los gangliósidos n-acetil gm3 y n-glicolil gm3 |
-
2012
- 2012-03-01 CU CU20120035A patent/CU24120B1/es active IP Right Grant
-
2013
- 2013-02-21 EP EP13713074.6A patent/EP2821417A2/en not_active Withdrawn
- 2013-02-21 AU AU2013225453A patent/AU2013225453A1/en not_active Abandoned
- 2013-02-21 SG SG11201405151YA patent/SG11201405151YA/en unknown
- 2013-02-21 KR KR1020147024181A patent/KR20140126349A/ko not_active Application Discontinuation
- 2013-02-21 WO PCT/CU2013/000001 patent/WO2013127373A2/es active Application Filing
- 2013-02-21 PE PE2014001340A patent/PE20142277A1/es not_active Application Discontinuation
- 2013-02-21 US US14/379,628 patent/US9527920B2/en not_active Expired - Fee Related
- 2013-02-21 CA CA2865050A patent/CA2865050A1/en not_active Abandoned
- 2013-02-21 MX MX2014010456A patent/MX2014010456A/es unknown
- 2013-02-21 EA EA201491618A patent/EA201491618A1/ru unknown
- 2013-02-21 JP JP2014559092A patent/JP5933044B2/ja not_active Expired - Fee Related
- 2013-02-21 CN CN201380011913.7A patent/CN104136463B/zh not_active Expired - Fee Related
- 2013-02-26 TW TW102106707A patent/TW201348259A/zh unknown
- 2013-02-28 AR ARP130100653A patent/AR090207A1/es unknown
-
2014
- 2014-07-31 TN TNP2014000330A patent/TN2014000330A1/fr unknown
- 2014-08-22 CL CL2014002236A patent/CL2014002236A1/es unknown
- 2014-08-27 CO CO14187637A patent/CO7051011A2/es unknown
- 2014-08-29 PH PH12014501950A patent/PH12014501950A1/en unknown
- 2014-08-31 IL IL234394A patent/IL234394A0/en unknown
- 2014-09-29 ZA ZA2014/07043A patent/ZA201407043B/en unknown
- 2014-12-02 HK HK14112117.7A patent/HK1198654A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013127373A3 (es) | 2013-10-31 |
| AU2013225453A1 (en) | 2014-09-25 |
| CU24120B1 (es) | 2015-08-27 |
| CN104136463A (zh) | 2014-11-05 |
| JP5933044B2 (ja) | 2016-06-08 |
| EP2821417A2 (en) | 2015-01-07 |
| CL2014002236A1 (es) | 2014-12-05 |
| ZA201407043B (en) | 2015-12-23 |
| WO2013127373A2 (es) | 2013-09-06 |
| US9527920B2 (en) | 2016-12-27 |
| CA2865050A1 (en) | 2013-09-06 |
| MX2014010456A (es) | 2014-10-13 |
| IL234394A0 (en) | 2014-10-30 |
| CU20120035A7 (es) | 2013-10-29 |
| PE20142277A1 (es) | 2015-01-15 |
| SG11201405151YA (en) | 2014-10-30 |
| US20150093385A1 (en) | 2015-04-02 |
| TW201348259A (zh) | 2013-12-01 |
| KR20140126349A (ko) | 2014-10-30 |
| JP2015516367A (ja) | 2015-06-11 |
| TN2014000330A1 (en) | 2015-12-21 |
| CO7051011A2 (es) | 2014-09-10 |
| PH12014501950A1 (en) | 2014-11-24 |
| EA201491618A1 (ru) | 2014-12-30 |
| CN104136463B (zh) | 2016-08-24 |
| EP2821417A9 (en) | 2015-04-01 |
| HK1198654A1 (en) | 2015-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019023754A2 (pt) | anticorpo anti-sirpalpha ou um fragmento de ligação ao antígeno do mesmo, composição farmacêutica, e, combinação do anticorpo anti-sirpalpha ou da composição farmacêutica. | |
| BR112015014751A8 (pt) | anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos. | |
| BR112015005048A2 (pt) | métodos para tratar dermatite atópica por administração de antagonista il-4r | |
| CU20110009A7 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| BR112015011403A2 (pt) | uso de akkermansia para o tratamento de distúrbios metabólicos | |
| AR089978A1 (es) | Translocaciones de la r-espondina y sus metodos de uso, metodo de tratamiento, antagonistas | |
| BR112016002401A2 (pt) | métodos para reduzir as taxas de exacerbação de asma usando benralizumab | |
| CR20110509A (es) | Composicion farmaceutica | |
| BR112014011331A2 (pt) | anticorpos específicos para trop-2 e seus usos | |
| EA201690377A1 (ru) | Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения | |
| BR112012001984B8 (pt) | anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica | |
| BR112014026740A2 (pt) | anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo | |
| MX348637B (es) | Anticuerpos y composiciones anti-her3. | |
| BR112015004875A2 (pt) | formulações de anticorpo e seus usos | |
| BR112014024282A2 (pt) | anticorpos ligantes ao receptor b1 da bradicinina | |
| BR112014018964A8 (pt) | Anticorpo anti-vegf e uso de um anticorpo anti-vegf | |
| EA201690992A1 (ru) | Антитела, специфичные к fcrn | |
| BR112015031950A2 (pt) | métodos para tratamento de câncer de ovário | |
| BR112015000616A2 (pt) | tratamento da esclerose múltipla com combinação de laquinimode e fampridina | |
| BR112016002462A8 (pt) | Métodos para melhorar os sintomas da asma usando benralizumabe | |
| AR090207A1 (es) | Anticuerpos recombinantes con especificidad dual por gangliosidos y su uso | |
| BR112015028997A2 (pt) | biomarcadores de expressão gênica e seu uso para a aplicação diagnóstica e prognóstica em pacientes potencialmente com necessidade de tratamento de inibidor de hdac | |
| BR112015031585A2 (pt) | composição farmacêutica | |
| CO6990729A2 (es) | Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósido n-glicolil gm3 (neugcgm3) | |
| AR119964A2 (es) | Anticuerpos anti-cd123 y conjugados y derivados de estos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |